If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  European Union Approves Dynepo (Erythropoietin) for Renal Disease-Related Anemia CAMBRIDGE, MA -- March 26, 2002 -- Transkaryotic Therapies, Inc. today announced that the European Commission has granted marketing authorization of Dynepo™ (epoietin delta) for the fifteen countries of the European Union. Dynepo is a human erythropoietin for the treatment of anemia related to renal disease in patients receiving dialysis and in patients who have not yet undergone dialysis to elevate and maintain red blood cell production. Under a collaborative agreement, Aventis Pharma, the pharmaceutical company of Aventis S.A., is responsible for the development and marketing activities of Dynepo. Dynepo, a fully human erythropoietin product, was developed using TKT's patented gene activation technology. Clinical testing in over 1,400 dialysis and pre-dialysis patients supported the approval of Dynepo as a treatment for anemia related to renal disease. A phase III study is ongoing to test Dynepo for anemia associated with cancer chemotherapy. Erythropoietin is a hormone that stimulates the production of red blood cells and is used primarily as a treatment for anemia associated with renal disease or cancer chemotherapy. Globally, more than 700,000 patients with end-stage renal failure experience anemia. By stimulating red blood cell production, erythropoietin is beneficial in the management and improvement of anemia. SOURCE: Transkaryotic Therapies, Inc.
|
